Population pharmacokinetic models for cefuroxime and metronidazole used in combination as prophylactic agents in colorectal surgery: Model-based evaluation of standard dosing regimens

International Journal of Antimicrobial Agents

Volumn 45, Issue 5, 2015, Pages 504-511

  Asín Prieto, Eduardo ^a   Soraluce, Amaia ^a   Trocóniz, Iñaki F ^b   Campo Cimarras, Eugenia ^c   Sáenz De Ugarte Sobrón, Jaione ^c   Rodríguez Gascón, Alicia ^a   Isla, Arantxazu ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c University Hospital of Alava   (Spain)

Author keywords

Cefuroxime; Colorectal surgery; Metronidazole; NONMEM; PK PD analysis; Population pharmacokinetics; Prophylaxis

Indexed keywords

ANTIINFECTIVE AGENT; CEFUROXIME; METRONIDAZOLE;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; CHEMISTRY; COLORECTAL SURGERY; FEMALE; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MIDDLE AGED; PLASMA; PROCEDURES; PROSPECTIVE STUDY; STATISTICAL MODEL; SURGICAL WOUND INFECTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; CEFUROXIME; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLORECTAL SURGERY; FEMALE; HALF-LIFE; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; MODELS, STATISTICAL; PLASMA; PROSPECTIVE STUDIES; SURGICAL WOUND INFECTION;

EID: 84933072543     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.01.008     Document Type: Article

References (30)

1. M. Watanabe, H. Suzuki, S. Nomura, K. Maejima, N. Chihara, and O. Komine et al. Risk factors for surgical site infection in emergency colorectal surgery: a retrospective analysis Surg Infect (Larchmt) 15 2014 256 261
2. R.L. Smith, J.K. Bohl, S.T. McElearney, C.M. Friel, M.M. Barclay, and R.G. Sawyer et al. Wound infection after elective colorectal resection Ann Surg 239 2004 599 605
3. K.W. Markell, B.M. Hunt, P.D. Charron, R.J. Kratz, J. Nelson, and J.T. Isler et al. Prophylaxis and management of wound infections after elective colorectal surgery: a survey of the American Society of Colon and Rectal Surgeons membership J Gastrointest Surg 14 2010 1090 1098
4. P. Moine, and D.N. Fish Pharmacodynamic modelling of intravenous antibiotic prophylaxis in elective colorectal surgery Int J Antimicrob Agents 41 2013 167 173
5. R.L. Nelson, E. Gladman, and M. Barbateskovic Antimicrobial prophylaxis for colorectal surgery Cochrane Database Syst Rev 5 2014 CD001181
6. D.W. Bratzler, and P.M. Houck Surgical Infection Prevention Guideline Writers Workgroup, Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project Am J Surg 189 2005 395 404
7. J.B. Bulitta, C.B. Landersdorfer, M. Kinzig, U. Holzgrabe, and F. Sorgel New semiphysiological absorption model to assess the pharmacodynamic profile of cefuroxime axetil using nonparametric and parametric population pharmacokinetics Antimicrob Agents Chemother 53 2009 3462 3471
8. M. Carlier, M. Noë, J.A. Roberts, V. Stove, A.G. Verstraete, and J. Lipman et al. Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: non-standard dosing approaches are required to achieve therapeutic exposures J Antimicrob Chemother 69 2014 2797 2803
9. A. Viberg, A. Lannergard, A. Larsson, O. Cars, M.O. Karlsson, and M. Sandstrom A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function Br J Clin Pharmacol 62 2006 297 303
10. C.A. Verhagen, H. Mattie, and E. Van Strijen The renal clearance of cefuroxime and ceftazidime and the effect of probenecid on their tubular excretion Br J Clin Pharmacol 37 1994 193 197
11. K.C. Lamp, C.D. Freeman, N.E. Klutman, and M.K. Lacy Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials Clin Pharmacokinet 36 1999 353 373
12. K.A. Sprandel, G.L. Drusano, D.W. Hecht, J.C. Rotschafer, L.H. Danziger, and K.A. Rodvold Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole Diagn Microbiol Infect Dis 55 2006 303 309
13. A.S. Levey, J. Coresh, T. Greene, J. Marsh, L.A. Stevens, and J.W. Kusek et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values Clin Chem 53 2007 766 772
14. US Food and Drug Administration Guidance for industry: bioanalytical method validation. Rockville, MD: US Department of Health and Human Services, Center for Drug Evaluation and Research; 2001. http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf [accessed 29.09.14].
15. European Medicines Agency Guideline on bioanalytical method validation. EMEA/CHMP/EWP/192217/2009. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2011/08/WC500109686.pdf [accessed 10.09.14].
16. P. Ruiz-Carretero, M. Merino-Sanjuán, A. Nácher, and V.G. Casabó Pharmacokinetic models for the saturable absorption of cefuroxime axetil and saturable elimination of cefuroxime Eur J Pharm Sci 21 2004 217 223
17. m) catalyst Drug Metab Dispos 41 2013 1686 1694
18. L. Lindbom, P. Pihlgren, and N. Jonsson PsN-Toolkit - a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM Comput Methods Program Biomed 79 2005 241 257
19. R.J. Keizer, M.O. Karlsson, and A. Hooker Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose CPT Pharmacometrics Syst Pharmacol 2 2013 e50
20. G. Kahlmeter Breakpoints for intravenously used cephalosporins in Enterobacteriaceae? EUCAST and CLSI breakpoints Clin Microbiol Infect 14 2008 169 174
21. K.L. Credito, L.M. Ednie, M.R. Jacobs, and P.C. Appelbaum Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology Antimicrob Agents Chemother 43 1999 2027 2031
22. European Committee on Antimicrobial Susceptibility Testing. Cefuroxime iv: rationale for the EUCAST clinical breakpoints, version 1.0. EUCAST; 2010. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Rationale-documents/Cefuroxime-iv-Rationale-Document-1.0-2010Nov.pdf [accessed 19.09.14].
23. European Committee on Antimicrobial Susceptibility Testing. Metronidazole: rationale for the EUCAST clinical breakpoints, version 1.0. EUCAST; 2010. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Rationale-documents/Metronidazole-rationale-1.0.pdf [accessed 19.09.14].
24. R.M. Savic, and M.O. Karlsson Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions AAPS J 11 2009 558 569
25. P.E. Gower, and C.H. Dash The pharmacokinetics of cefuroxime after intravenous injection Eur J Clin Pharmacol 12 1977 221 227
26. M.J. Koot, F.N. I.Jdenberg, R.M. Stuurman, J. Poell, L.J. Bras, and J.J. Langemeijer et al. High pressure liquid chromatographic analysis of the serum concentration of cefuroxime after an intravenous bolus injection of cefuroxime in patients with a coronary artery bypass grafting Pharm Weekbl Sci 14 1992 360 364
27. A. Barbour, S. Schmidt, W.R. Rout, K. Ben-David, O. Burkhardt, and H. Derendorf Soft tissue penetration of cefuroxime determined by clinical microdialysis in morbidly obese patients undergoing abdominal surgery Int J Antimicrob Agents 34 2009 231 235
28. J.H. Solhaug, T. Bergan, O. Leinebo, A.R. Rosseland, L. Spada, and F. Vaagenes The pharmacokinetics of one single preoperative dose of metronidazole or tinidazole Scand J Gastroenterol Suppl 90 1984 89 96
29. D.W. Bratzler, E.P. Dellinger, K.M. Olsen, T.M. Perl, P.G. Auwaerter, and M.K. Bolon et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery Surg Infect (Larchmt) 14 2013 73 156
30. M. Ulldemolins, J.A. Roberts, J. Rello, D.L. Paterson, and J. Lipman The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients Clin Pharmacokinet 50 2011 99 110